CClinicalTrials.gg
Status unknownNCT02674139Updated Sep 27, 2016

Comparison Between Intrauterine Contraceptive Device Insertion During Cesarean Section Vs Conventional Application

A Phase 4 interventional study of Copper T 380A IUD in Contraception, sponsored by sara AbdAllah. Status unknown. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-09-27.

Sponsored by sara AbdAllah · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2016), so the status shown — last known as Enrolling by invitation — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The study aims to compare immediate post-placental (within 10 minutes of placenta delivery) intrauterine contraceptive device (Copper T 380A) insertion versus conventional placement at 6 weeks (often referred to as delayed or interval insertion) regarding the clinical outcomes (safety, efficacy, expulsion and continuation rates) for women undergoing caesarean section.

Read the detailed description
  • Study Design: A controlled randomized clinical trial (CRCT)
  • Study Site: The study will be carried out in the Department of Obstetrics and Gynecology at Beni-suef University Hospital
  • Study Population: The study population will include pregnant women between 36-40 weeks gestational ages who attend antenatal care and are eligible for insertion of IUCD during delivery through elective caesarean section.
  • Study Sample: The study will consist of 200 women which will be chosen randomly to whom elective lower segment caesarean section will be done at the Obstetrics and Gynecology department, willing to have an intrauterine device (IUD) inserted for postpartum contraception and willing to comply with the study protocol.

After informed consent is obtained, eligible study participants will be randomized into 2 groups:

Group (A): 100 Women will receive the Pregna ® IUD at the 6 week postpartum visit Group (B): 100 Women will receive the Pregna ® IUD within 10 minutes of delivery of the placenta during caesarean section.

  • Study Procedure:

Insertion Technique:

During caesarean section:

Uterine cavity will be inspected for presence of malformations following placental delivery, which would limit use of IUCD.The IUCD (Pregna Copper T 380A) will be removed from the insertion sleeve and will be placed on the sterile field. Uterus is stabilized by grasping it at fundus. Insertion will be done during cesarean delivery, after ex pulsion of placenta and through the uterine incision, manually (IUCD is Held between middle and index finger). It will be inserted into the uterus through uterine incision and will be released at fundus of uterus. Hand will be removed slowly from the uterus. Enough care will be taken not to dislodge IUCD as hand is removed. Strings will be guided toward the lower uterine segment without disturbing IUCD'S fundal position. Enough Care will be taken not to include IUCD strings during uterine closure.

Delayed postpartum IUDs Will be inserted in the usual sterile fashion as described in the manufacturer's instructions at the 6-week postpartum visit

Later Prior to Discharge:

  • IUCD Client card, showing type of IUCD and date of insertion will be given to patient.
  • She will be informed about the IUCD side effects and normal postpartum symptoms.

    • Patients will be scheduled for a control examination at 1 week, 6 weeks, 3 months and 6 months after the insertion.
    • She will be advised to contact one of the physicians immediately if they experienced:-
    • Unusual vaginal discharge different from the usual lochia.
    • Lower abdominal pain, especially if accompanied by fever or chills.
    • Feeling of being pregnant.
    • Suspicion that the IUCD has fallen out.

Follow up visits:

  • At each visit the patients will be questioned for symptoms of expulsion, excessive bleeding and infection. In addition, a pelvic examination (per speculum) and trans-vaginal ultrasound will be performed at each follow-up visit.
  • In per speculum examination if IUD threads are long, they will be cut 2 cm from external os. If threads of IUD are not seen and there was no history of expulsion of IUD, pelvic ultrasonography or X-ray pelvis will be done to note for misplaced IUD.
  • All the patients will subjected to the follow up:
  • The IUD will be removed in the case of partial expulsion, bleeding or pain, or at the patient's request.

    • Ethical Considerations

      1-Approval by the institution ethical committee 2-Individual Consent Process: Written informed consent will be taken after explaining the study objective the procedures to potential participants. Participation will be voluntary and participants will be informed that the decision not to participate will not impact on the quality of care they receive.

    • The statistical Analysis:

Data will be statistically described in terms of mean + standard deviation (+/- SD), frequencies (number of cases) and relative frequencies (percentages) when appropriate. Comparison of numerical variables between the study groups will be done using Student t test for independent samples. For comparing categorical data, Chi square (X2) test will be performed. Exact test will be used instead when the expected frequency is less than 5. P values less than 0.05 will be considered statistically significant.

02

Conditions studied

  • Contraception

Keywords

  • post placental-caesarean-IUD
03

In context

Lead sponsor

This is the only study on the registry with sara AbdAllah as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age: 18 - 45 years.
  • GA 36-40 weeks based upon the date of last normal menstruation, confirmed by ultrasonographic scan.
  • Desire to have intrauterine contraceptive device (Cu T) after counseling about different contraceptive options and consented to the study.

Exclusion criteria

Exclusion criteria:

  • Allergy to copper.
  • Ante- or intra-partum hemorrhage.
  • Hemorrhagic disorders.
  • Current or past history of pelvic inflammatory disease.
  • Women known to have pelvic TB.
  • Known to have ruptured membranes for more than 24 h prior to delivery.
  • History of chorioamnionitis.
  • Known uterine abnormalities e.g., Bicornuate/septate Uterus, uterine myoma.
  • Patients presented with febrile morbidity prior to the operation defined as temperature above 38'c.
  • Multiple pregnancies.
  • Placenta previa.
  • History of ectopic pregnancy.
  • Anemia (hemoglobin \<10 g/dl).
  • Cervical cancer or carcinoma in situ.
  • Diagnosis of active cervical infection for standard insertion.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Active comparator
    IUD insertion 6 Weeks after delivery

    Subjects randomized to interval placement will have their Copper T 380A IUD placed in the office at six weeks postpartum or later

    Device: Copper T 380A IUD

  • Experimental
    Immediate Post-placental insertion

    Subjects randomized to receive the Copper T 380A IUD within 10 minutes of delivery of the placenta during caesarean section.

    Device: Copper T 380A IUD

Interventions

  • DeviceCopper T 380A IUD

    intrauterine contraceptive device T-shaped loaded with cupper

    Also known as: Pregna

06

What researchers measure

Primary outcomes

  1. Expulsion: Complete IUD expulsion will be verified clinically and by transvaginal ultrasound

    Complete IUD expulsion will be verified clinically and by transvaginal ultrasound. An IUD will be considered to be partially expelled if a distance greater than 10 mm is measured between the vertical arm of the IUD and the junction between the endometrium and the uterine cavity)

    Time frame: 6 months

Secondary outcomes

  1. Uterine perforation (assessed by pelvic ultrasonography or X-ray)

    To be assessed by pelvic ultrasonography or X-ray pelvis will to note for misplaced IUD

    Time frame: 6 months

  2. Pelvic pain (using the 0-10 Numeric Pain Rating Scale)

    Using the 0-10 Numeric Pain Rating Scale and analgesic doses required

    Time frame: 6 months

  3. Strings not visible (assessed by speculum examination)

    To be assessed by speculum examination.

    Time frame: 6 months

  4. Pelvic infection: number of participants with Pelvic infection

    number of participants with Pelvic infection

    Time frame: 6 months

  5. Psychological (satisfied or not) using questionnaire

    using questionnaire

    Time frame: 6 months

  6. Pregnancy (assessed by serum pregnancy test and pelvic ultrasound)

    To be assessed by serum pregnancy test and pelvic ultrasound in suspicious cases (missed period - misplaced IUD - expelled IUCD either partial or complete)

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 27, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02674139
Lead sponsor
sara AbdAllah
Collaborators
Beni-Suef University
Responsible party
sara AbdAllah (Assistant lecturer of Obstetrics and Gynecology Faculty of Medicine- Beni-sueif University, Beni-Suef University) — Sponsor-investigator
First posted
Feb 4, 2016
Start date
Feb 2016
Primary completion
Mar 2017 (estimated)
Completion
Jun 2017 (estimated)
Last update
Sep 27, 2016

Study contacts

sara AA mohamed, master
principal investigator

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion